Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial by Gallant, J. et al.
www.thelancet.com   Vol 390   November 4, 2017 2063
Bictegravir, emtricitabine, and tenofovir alafenamide versus 
dolutegravir, abacavir, and lamivudine for initial treatment of 
HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, 
phase 3, randomised controlled non-inferiority trial
Joel Gallant, Adriano Lazzarin, Anthony Mills, Chloe Orkin, Daniel Podzamczer, Pablo Tebas, Pierre-Marie Girard, Indira Brar, Eric S Daar, 
David Wohl, Jürgen Rockstroh, Xuelian Wei, Joseph Custodio, Kirsten White, Hal Martin, Andrew Cheng, Erin Quirk
Summary
Background Integrase strand transfer inhibitors (INSTIs) are recommended components of initial antiretroviral 
therapy with two nucleoside reverse transcriptase inhibitors. Bictegravir is a novel, potent INSTI with a high in-vitro 
barrier to resistance and low potential as a perpetrator or victim of clinically relevant drug–drug interactions. We 
aimed to assess the efficacy and safety of bictegravir coformulated with emtricitabine and tenofovir alafenamide as a 
fixed-dose combination versus coformulated dolutegravir, abacavir, and lamivudine.
Methods We did this double-blind, multicentre, active-controlled, randomised controlled non-inferiority trial at 
122 outpatient centres in nine countries in Europe, Latin America, and North America. We enrolled HIV-1 infected 
adults (aged ≥18 years) who were previously untreated (HIV-1 RNA ≥500 copies per mL); HLA-B*5701-negative; had 
no hepatitis B virus infection; screening genotypes showing sensitivity to emtricitabine, tenofovir, lamivudine, and 
abacavir; and an estimated glomerular filtration rate of 50 mL/min or more. Participants were randomly assigned 
(1:1), via a computer-generated allocation sequence (block size of four), to receive coformulated bictegravir 50 mg, 
emtricitabine 200 mg, and tenofovir alafenamide 25 mg or coformulated dolutegravir 50 mg, abacavir 600 mg, and 
lamivudine 300 mg, with matching placebo, once daily for 144 weeks. Randomisation was stratified by HIV-1 RNA 
(≤100 000 copies per mL, >100 000 to ≤400 000 copies per mL, or >400 000 copies per mL), CD4 count (<50 cells 
per μL, 50–199 cells per μL, or ≥200 cells per μL), and region (USA or ex-USA). Investigators, participants, and study 
staff giving treatment, assessing outcomes, and collecting data were masked to group assignment. The primary 
endpoint was the proportion of participants with plasma HIV-1 RNA less than 50 copies per mL at week 48, as defined 
by the US Food and Drug Administration snapshot algorithm, with a prespecified non-inferiority margin of –12%. All 
participants who received one dose of study drug were included in primary efficacy and safety analyses. This trial is 
registered with ClinicalTrials.gov, number NCT02607930.
Findings Between Nov 13, 2015, and July 14, 2016, we randomly assigned 631 participants to receive coformulated 
bictegravir, emtricitabine, and tenofovir alafenamide (n=316) or coformulated dolutegravir, abacavir, and lamivudine 
(n=315), of whom 314 and 315 patients, respectively, received at least one dose of study drug. At week 48, HIV-1 RNA 
less than 50 copies per mL was achieved in 92·4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and 
tenofovir alafenamide group and 93·0% of patients (n=293 of 315) in the dolutegravir, abacavir, and lamivudine group 
(difference –0·6%, 95·002% CI –4·8 to 3·6; p=0·78), demonstrating non-inferiority of bictegravir, emtricitabine, and 
tenofovir alafenamide to dolutegravir, abacavir, and lamivudine. No individual developed treatment-emergent 
resistance to any study drug. Incidence and severity of adverse events was mostly similar between groups except for 
nausea, which occurred less frequently in patients given bictegravir, emtricitabine, and tenofovir alafenamide than in 
those given dolutegravir, abacavir, and lamivudine (10% [n=32] vs 23% [n=72]; p<0·0001). Adverse events related to 
study drug were less common with bictegravir, emtricitabine, and tenofovir alafenamide than with dolutegravir, 
abacavir, and lamivudine (26% [n=82] vs 40% [n=127]), the difference being driven by a higher incidence of drug-
related nausea in the dolutegravir, abacavir, and lamivudine group (5% [n=17] vs 17% [n=55]; p<0·0001).
Interpretation At 48 weeks, coformulated bictegravir, emtricitabine, and tenofovir alafenamide achieved virological 
suppression in 92% of previously untreated adults and was non-inferior to coformulated dolutegravir, abacavir, and 
lamivudine, with no treatment-emergent resistance. Bictegravir, emtricitabine, and tenofovir alafenamide was safe 
and well tolerated with better gastrointestinal tolerability than dolutegravir, abacavir, and lamivudine. Because 
coformulated bictegravir, emtricitabine, and tenofovir alafenamide does not require HLA B*5701 testing and 
provides guideline-recommended treatment for individuals co-infected with HIV and hepatitis B, this regimen 
might lend itself to rapid or same-day initiation of therapy in the clinical setting.
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Introduction
Integrase strand transfer inhibitor (INSTI)-containing 
regimens are widely recommended for the treatment of 
HIV-1 infection, and in many settings have become the 
standard of care for initial therapy in combination with 
two nucleoside reverse transcriptase inhibitors (NRTIs).1–3 
Three INSTIs are currently approved: raltegravir, elvite-
gravir, and dolutegravir. No coformulations of raltegravir 
with NRTIs are commercially available, and patients 
receiving the twice-daily or once-daily formulations 
have to take two pills per day, not including the NRTI 
com ponent. Elvitegravir is available in two once-daily, 
single-tablet coformulations, but requires boosting by 
the CYP3A4 inhibitor and pharmacokinetic enhancer, 
cobic istat, resulting in the potential for drug–drug 
interactions with medications primarily metabolised by 
CYP3A4. Elvite gravir is restricted to patients with an 
estimated glomerular filtration rate (eGFR) of more than 
30 mL/min. Raltegravir and elvitegravir have overlapping 
resistance profiles. Dolutegravir is a once-daily, unboosted 
INSTI with a higher barrier to resistance than raltegravir 
or elvitegravir, and is available as a single drug or 
coformulated with abacavir and lamivudine. Abacavir is 
associated with risk of hypersensitivity reaction, requires 
pretreatment HLA-B*5701 testing, has no activity against 
hepatitis B virus, and has been associated with an 
increased risk of cardiovascular events.3–10 No underlying 
pathophysiological mechanism has been defined for 
this possible association. Coformulations that include 
abacavir and lamivudine are indicated only for patients 
with an eGFR of more than 50 mL/min. Although CNS 
adverse effects, including depression, anxiety, and 
insomnia, might be a class effect of INSTIs, some 
evidence suggests that these events occur more frequently 
with dolutegravir in clinical practice than reported in 
clinical trials.11–13 Hypersensitivity reactions have also 
been reported with dolutegravir.14
Bictegravir (formerly GS-9883) is a novel, potent, once-
daily, unboosted INSTI with a high in-vitro barrier to 
resistance and in-vitro activity against most INSTI-
resistant variants, including several variants that have 
reduced susceptibility to dolutegravir.15,16 Findings from 
clinical studies show that bictegravir has a half-life of 
roughly 18 h, can be given with or without food, 
Research in context
Evidence before this study
We searched PubMed between Jan 1, 1997, and June 5, 2017, 
for randomised clinical trials of dolutegravir and bictegravir 
(GS-9883) in patients with HIV-1, with title or abstract search 
terms of “dolutegravir” or “bictegravir” or “randomised” or 
“randomized”. Searches were limited to articles published in 
English. Our search yielded two articles for bictegravir or 
GS-9883: one article summarising results of a short-term 
monotherapy and pharmacokinetic study and the other 
summarising results from a phase 2 study comparing 
bictegravir with dolutegravir, each given with the 
recommended nucleoside reverse transcriptase inhibitor (NRTI) 
combination of emtricitabine and tenofovir alafenamide in 
treatment-naive adults with HIV infection. Both treatments 
showed high efficacy and were well tolerated up to 48 weeks.
The search also yielded 25 articles for dolutegravir. We removed 
22 of these articles because they were short-term monotherapy 
or pharmacokinetic studies or systemic reviews or 
meta-analyses, and selected the three remaining articles for 
further review. These studies showed non-inferiority of regimens 
containing dolutegravir to those containing raltegravir, and 
superiority of regimens containing dolutegravir to those 
containing darunavir plus ritonavir, atazanavir plus ritonavir, or 
efavirenz. Findings also showed antiviral activity of dolutegravir 
in integrase strand transfer inhibitor (INSTI)-resistant 
populations. Treatment with dolutegravir was well tolerated.
Added value of this study
INSTIs are recommended as first-line antiretroviral therapy in 
combination with two NRTIs. Bictegravir is a novel, potent 
INSTI with high in-vitro activity against most INSTI-resistant 
viruses and low potential to perpetrate drug–drug interactions, 
although it can be a victim of potent CYP3A4 inducers. 
Bictegravir has been coformulated with emtricitabine and 
tenofovir alafenamide as a fixed-dose combination. This NRTI 
backbone is recognised for its potency and safety advantages, 
particularly with respect to bone and renal measures as 
compared with emtricitabine and tenofovir disoproxil 
fumarate. It does not require pretreatment HLA-B*5701 
testing, trigger hypersensitivity reactions, or have any known 
association with cardiovascular events as reported with 
abacavir and lamivudine. Moreover, HIV guidelines recommend 
tenofovir alafenamide or tenofovir disoproxil fumarate as 
components of regimens for treatment of individuals 
co-infected with HIV and hepatitis B virus. This is the first 
phase 3 clinical trial comparing the fixed-dose combination of 
bictegravir, emtricitabine, and tenofovir alafenamide with 
coformulated dolutegravir, abacavir, and lamivudine.
Implications of all the available evidence
Our findings demonstrate non-inferiority of coformulated 
bictegravir, emtricitabine, and tenofovir alafenamide versus 
coformulated dolutegravir, abacavir, and lamivudine for initial 
treatment of HIV infection. In both groups, virological response 
was rapid and efficacy was high. Coformulated bictegravir, 
emtricitabine, and tenofovir alafenamide is a potent, novel, 
unboosted INSTI-based regimen with favourable tolerability, 
and can be administered once daily. Because this regimen does 
not require HLA B*5701 testing and provides guideline-
recommended therapy for individuals co-infected with HIV and 
hepatitis B virus, this combination might lend itself to rapid or 
same-day initiation of therapy in the clinical setting.
is eliminated by hepatic metabolism with similar contri-
butions of CYP3A4 and UGT1A1, and has low potential for 
clinically meaningful drug–drug interactions, but can be 
affected by drugs that are potent inducers of CYP3A4.16 
Bictegravir, at doses ranging from 5 mg to 100 mg daily in 
HIV-infected adults, showed rapid, dose-dependent 
declines in HIV-1 RNA after 10 days of monotherapy in a 
phase 1b placebo-controlled study evaluating its short-term 
antiviral potency.17 Bictegravir was well tolerated, and 
displayed rapid absorption and a half-life supportive of 
once-daily therapy.
In a phase 2 trial comparing bictegravir with dolute-
gravir, both in combination with emtricitabine and 
tenofovir alafenamide, both regimens were well tolerated 
with no clinically significant toxic effects or tolerability 
differences, and 48 week efficacy was high and similar 
between groups.18 We did the GS-US-380-1489 study to 
compare the efficacy and safety of coformulated bicte-
gravir, emtricitabine, and tenofovir alafenamide with 
coformulated dolutegravir, abacavir, and lamivudine in 
HIV-1-infected, previously untreated adults.
Methods
Study design and participants
We did this double-blind, multicentre, active-controlled, 
phase 3, randomised controlled non-inferiority trial at 
122 outpatient centres in nine countries in Europe 
(Belgium, France, Germany, Italy, Spain, and the UK), 
Latin America (Dominican Republic), and North America 
(Canada and the USA). Study investigators enrolled HIV-1-
infected adults (aged ≥18 years) who were previously 
untreated and had plasma HIV-1 RNA concentrations of 
500 copies per mL or more, no hepatitis B virus infection, 
were HLA-B*5701-negative, had an eGFR of 50 mL/min or 
more (Cockcroft–Gault equation), and had no documented 
resistance to emtricitabine, tenofovir, abacavir, or 
lamivudine. This study was done in accordance with the 
Declaration of Helsinki and was approved by central or 
site-specific review boards or ethics committees. All 
participants gave written informed consent. 
Randomisation and masking
Participants were randomly assigned (1:1), via a computer-
generated allocation sequence (block size of four) created 
by Bracket (San Francisco, CA, USA), to receive once-
daily fixed-dose combinations of either bictegravir 50 mg, 
emtricitabine 200 mg, and tenofovir alafenamide 25 mg 
or dolutegravir 50 mg, abacavir 600 mg, and lamivudine 
300 mg, with matching placebo. Randomisation was 
stratified by HIV-1 RNA (≤100 000 copies per mL, 
>100 000 to ≤400 000 copies per mL, or >400 000 copies
per mL), CD4 count (<50 cells per μL, 50–199 cells per μL,
or ≥200 cells per μL), and region (USA or ex-USA).
Investigators, participants, and study staff giving treat-
ment, assessing outcomes, and collecting data were
masked to group assignment. Study investigators deter-
mined eligibility, obtained a participant number, and
received automated treatment assignment on the basis of 
a randomisation sequence.
Procedures
Both regimens were given without regard to food. Post-
baseline study visits were done at weeks 4, 8, 12, 24, 36, 
and 48, after which participants will continue masked 
treatment with visits every 12 weeks until week 144. 
Laboratory tests included haematological analysis, serum 
chemistry tests, fasting lipid measures, CD4 cell counts, 
measures of renal function (eGFR, urine albumin to 
creatinine ratio, retinol binding protein to creatinine 
ratio, β2-microglobulin to creatinine ratio; Covance 
Laboratories, Indianapolis, IN, USA), and measurement 
of HIV-1 RNA (Roche TaqMan 2.0; Roche Diagnostics, 
Rotkreuz, Switzerland). Protocol-defined resistance 
testing consisted of genotyping and phenotyping of 
integrase, protease, and reverse transcriptase (Monogram 
Biosciences, South San Francisco, CA, USA) for any 
participant who had an HIV-1 RNA of at least 50 copies 
per mL with a confirmed HIV-1 RNA of at least 200 copies 
per mL or who had an HIV-1 RNA of at least 200 copies 
per mL at week 48 or at the last visit on study drug. 
We did dual energy X-ray absorptiometry scans for hip 
and spine lumbar bone mineral density before drug 
administration at baseline, week 24, and week 48. A 
centralised centre masked to group assignment read all 
scans (BioClinica, Newtown, PA, USA). Safety was 
assessed by physical examinations, laboratory tests, 
12-lead electrocardiogram, concomitant drugs, and
recording of adverse events, which were coded with the
Medical Dictionary for Regulatory Activities (version 19.1).
Relatedness of adverse events to study drugs was indicated 
by the investigator in a binary manner (yes or no). The
pharmacokinetics of bictegravir, emtricitabine, and teno-
fovir alafenamide were assessed through an intensive
pharmacokinetic substudy done on a non-randomised
subset of participants. A trough pharmacokinetic blood
sample was obtained at the week 4 or 8 visit 20–28 h after
the last dose of bictegravir, emtricitabine, and tenofovir
alafenamide, and post-dose pharmacokinetic blood
samples were obtained at 0·5, 1, 1·5, 2, 3, 4, 6, 8, and 24 h
post dose after an observed dose at the clinic. Plasma
concentrations of bictegravir, emtricitabine, and tenofovir
alafenamide were determined by use of fully validated
high-performance liquid chromatography–tandem mass
spectroscopy bioanalytical methods.
Outcomes
The primary outcome was the proportion of participants 
with plasma HIV-1 RNA less than 50 copies per mL at 
week 48, as defined by the US Food and Drug 
Administration (FDA) snapshot algorithm.19 Additional 
prespecified efficacy endpoints included virological 
efficacy by subgroups of age, sex, race, baseline HIV-1 
RNA, baseline CD4 cell count, geographical region, 
and study medication adherence; the proportion of 
participants with plasma HIV-1 RNA less than 50 copies 
per mL at week 48 after imputation of missing-as-failure 
and missing-as-excluded values; participants with HIV-1 
RNA less than 20 copies per mL at week 48 by the 
snapshot algorithm; and change in HIV-1 RNA and CD4 
cell count from baseline to week 48.
Other prespecified secondary outcomes included per-
centage changes from baseline in hip and lumbar spine 
bone mineral density at week 48, change from baseline in 
serum creatinine and eGFR at week 48, and percentage 
changes from baseline in urine retinol binding protein to 
creatinine ratio, urine β2-microglobulin to creatinine ratio, 
and urine albumin to creatinine ratio at week 48.
Statistical analysis
We analysed the primary endpoint in the full analysis set 
(all participants who were randomly assigned and had 
received at least one dose of the study drug, regardless of 
whether they returned for post-baseline assessments) after 
enrolled participants had completed their week 48 study 
visit or had prematurely discontinued the study drug. 
We assessed the primary assessment of non-inferiority 
with a conventional 95% CI approach for the difference 
in virological response rates (bicte gravir, emtricitabine, 
and tenofovir alafenamide minus dolutegravir, abacavir, 
and lamivudine) with a prespecified non-inferiority mar-
gin of –12%, based on published US FDA regulatory 
guidance.20
With an assumed response rate of 91% at week 48 for 
both treatment groups, a sample size of 600 participants 
would achieve at least 95% power to detect non-inferiority 
at a one-sided α of 0·025. Two planned interim analyses 
by the independent data monitoring committee were 
done after roughly the first 50% of enrolled participants 
had completed their week 12 study visit or had 
prematurely discontinued study drugs, and again when 
all subjects completed their week 24 study visit or had 
prematurely discontinued study drugs. Both analyses 
concluded that efficacy and safety findings warranted 
continuation of the trial. An α penalty of 0·00001 was 
applied for each planned interim analysis. Therefore, the 
significance level for the two-sided non-inferiority test at 
week 48 was 0·04998, corresponding to a 95·002% CI. 
We constructed the baseline stratum-weighted difference 
in the response rate and its 95·002% CI based on 
Mantel–Haenszel proportion adjusted by baseline HIV-1 
RNA (≤100 000 or >100 000 copies per mL) and region 
(USA or ex-USA).
In the FDA snapshot analysis, participants were 
classified according to three outcomes: (1) HIV-1 RNA 
less than 50 copies per mL at week 48 (between days 295 
and 378, inclusive); (2) HIV-1 RNA of 50 copies per mL 
or more, including participants with HIV-1 RNA of 
50 copies per mL or more at week 48, participants who 
discontinued study drug before week 48 because of low 
efficacy, or participants who discontinued study drug 
because of reasons other than low efficacy, adverse event, 
and death before week 48 with last available HIV-1 RNA 
of 50 copies per mL or more; and (3) no virological data 
in the week 48 window, including participants who 
discontinued study drug before week 48 because of 
adverse events or death; participants who discontinued 
study drug because of reasons other than low efficacy, 
adverse event, and death before week 48 with last 
available HIV-1 RNA less than 50 copies per mL; and 
participants who were still on study drug with missing 
HIV-1 RNA data at week 48. The difference in response 
rates and p value of the snapshot analysis were calculated 
based on the dichotomised response: HIV-1 RNA less 
than 50 copies per mL at week 48 versus HIV-1 RNA of 
50 copies per mL or more and no virological data at 
week 48.
Subgroup analyses of the primary endpoint were done 
based on age, sex, race, baseline HIV-1 RNA, baseline 
CD4 cell count, geographical region, and adherence to 
study drug. Adherence was computed as number of pills 
taken divided by number of pills prescribed, whereby the 
number of pills taken was the number of pills dispensed 
minus the number of pills returned. We also analysed 
the primary efficacy endpoint in the per-protocol analysis 
set, which excluded participants in the full analysis set 
who did not have an HIV-1 RNA value in the week 48 
Figure 1: Trial profile
B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine.
739 individuals screened
631 randomly assigned
89 did not meet eligibility criteria
19 met eligibility criteria but not 
randomly assigned
8 lost to follow-up
6 withdrew consent
2 at investigator’s discretion
1 adverse event
1 outside visit window
1 other
315 assigned to receive DTG/ABC/3TC
315 treated
299 continued on treatment
16 discontinued
4 had an adverse event
1 had non-compliance with 
study drugs
5 at participant’s decision
6 lost to follow-up
316 assigned to receive B/F/TAF
314 treated
2 never treated
295 continued on treatment
19 discontinued
1 had a pregnancy
3 at investigator’s discretion
1 had non-compliance with 
study drugs
1 had a protocol violation
4 at participant’s decision
9 lost to follow-up
analysis window and those who had low adherence (ie, 
adherence ≤2·5th percentile). Additionally, the week 48 
efficacy endpoint was analysed with a HIV-1 RNA cutoff 
of less than 20 copies per mL by snapshot analysis, and 
the proportion of participants with plasma HIV-1 RNA 
less than 50 copies per mL at week 48 was analysed 
with imputation of missing-as-failure and missing-as-
excluded values.
Change from baseline in log10 HIV-1 RNA and CD4 cell 
count at week 48 was summarised by treatment group 
with descriptive statistics based on the full analysis set. 
Differences in changes from baseline in log10 HIV-1 RNA 
and CD4 cell count between treatment groups were 
constructed with an ANOVA model, including treatment 
group, baseline HIV-1 RNA stratum (≤100 000 copies 
per mL vs >100 000 copies per mL), and region as fixed 
covariates.
We summarised baseline characteristics with des-
criptive statistics for the safety analysis set, which 
included all randomly assigned participants who 
received at least one dose of study drug. Safety data are 
described in summary form, with use of all data collected 
from after study drug was first given to the data cutoo 
date or up to 30 days after the last dose of study drug, if 
the participant discontinued treatment. For categorical 
data, we calculated p values with the Cochran–Mantel–
Haenszel test (the general association statistic was used 
for nominal data and the row mean scores differ statistic 
for ordinal data) for treatment comparison. We used 
two-sided Wilcoxon rank-sum testing for continuous 
data. To minimise the effect o f m ultiple c omparison, 
statistical comparisons of the incidence of adverse 
events between the two treatment groups were made 
with Fisher’s exact test for adverse events occurring with 
more than a 5% difference in incidence between groups. 
For bone mineral density, differences i n p ercentage 
changes from baseline between treatment groups, and 
their 95% CIs and p values, were constructed with 
ANOVA, including treatment group as a fixed effect in 
the model.
We did analyses with SAS (version 9.4). Pharmacokinetic 
measures were calculated by application of a non-
linear model with standard non-compartmental analysis 
(WinNonlin version 6.4). This trial is registered with 
ClinicalTrials.gov, number NCT02607930.
Role of the funding source
The funder of the study had a role in study design, data 
collection, data analysis, data interpretation, and writing 
of the report. The corresponding author (HM) had full 
access to all the data in the study. JG, HM, EQ, and AC 
had final r esponsibility f or t he d ecision t o s ubmit f or 
publication. 
Results
Between Nov 13, 2015, and July 14, 2016, we randomly 
assigned 631 patients to receive bictegravir, emtricitabine, 
and tenofovir alafenamide (n=316) or dolutegravir, 
abacavir, and lamivudine (n=315), of whom 314 and 
315 patients, respectively, received at least one dose of 
study drug (figure 1). Demographics and baseline 
characteristics were similar between groups (table 1).
Bictegravir, emtricitabine, and tenofovir alafenamide 
was non-inferior to dolutegravir, abacavir, and lamivudine 
for the primary outcome of proportion of partici pants with 
plasma HIV-1 RNA less than 50 copies per mL at week 48 
(92·4% [n=290] vs 93·0% [n=293]; difference −0·6%, 
95·002% CI −4·8 to 3·6; p=0·78; table 2). Between-group 
efficacy did not differ significantly among the various 





Age (years) 31 (18–71) 32 (18–68)
Sex
Female 29 (9%) 33 (10%)
Male 285 (91%) 282 (90%)
Race
White 180 (57%) 179 (57%)
Black 114 (36%) 112 (36%)
Asian 6 (2%) 10 (3%)
American Indian or 
Alaska Native
2 (1%) 4 (1%)
Native Hawaiian or 
Pacific Islander
1 (<1%) 2 (1%)
Other 9 (3%) 8 (3%)
Not permitted 2 (1%) 0
Hispanic or Latino 72 (23%) 65 (21%)
HIV disease status
Asymptomatic 286 (91%) 286 (91%)
Symptomatic 16 (5%) 14 (4%)
AIDS 12 (4%) 15 (5%)
HIV risk factor
Heterosexual sex 61 (19%) 62 (20%)
Homosexual sex 251 (80%) 250 (79%)
Intravenous drug use 5 (2%) 4 (1%)
HIV-1 RNA (log10 copies 
per mL)
4·42 (4·03–4·87) 4·51 (4·04–4·87)
HIV-1 RNA >100 000 
copies per mL
53 (17%) 50 (16%)
CD4 count (cells per μL) 443 (299–590) 450 (324–608)
<50 7 (2%) 10 (3%)
≥50 to <200 29 (9%) 22 (7%)
≥200 to <350 69 (22%) 58 (18%)
≥350 to <500 87 (28%) 91 (29%)
≥500 122 (39%) 134 (43%)
Creatinine clearance 
(mL/min)*
125·9 (107·7–146·3) 123·0 (107·0–144·3)
Body-mass index (kg/m²) 25·1 (22·4–28·7) 24·9 (22·5–29·1)
Data are median (IQR [range for age]) or n (%). B/F/TAF=bictegravir, 
emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, 
abacavir, and lamivudine. *Estimated with the Cockcroft–Gault equation.
Table 1: Baseline demographic and clinical characteristics
See Online for appendix
The proportion of participants with HIV-1 RNA less than 
20 copies per mL at week 48 was 87·6% (n=275) in the 
bictegravir, emtricitabine, and tenofovir alafenamide group 
and 87·3% (n=275) in the dolutegravir, abacavir, and lam-
ivudine group (difference 0·4%, 95% CI –4·8 to 5·6; 
p=0·87).
The proportion of participants with HIV-1 RNA less 
than 50 copies per mL was high in both groups in the per-
protocol analysis (99·3% [n=287 of 289] in the bictegravir, 
emtricitabine, and tenofovir alafenamide group vs 98·6% 
[n=289 of 293] in the dolutegravir, abacavir, and 
lamivudine group; difference 0·7%, 95·002% CI 
–1·4 to 2·8; p=0·43). Results of the missing-as-failure
and missing-as-excluded analyses were consistent with
those of the primary analysis (table 2). HIV-1 RNA
concentrations decreased in each treatment group, with
the fastest decreases from baseline observed in the first
4 weeks after initiation of study drugs (appendix p 5). In
missing-as-excluded analysis, the proportion of 
participants with HIV-1 RNA less than 50 copies per mL
was 77·4% (n=243 of 314) in the bictegravir, emtricitabine, 
and tenofovir alafenamide group and 75·9% (n=236 of
311) in the dolutegravir, abacavir, and lamivudine group at 
week 4 and 91·7% (n=286 of 312) and 91·6% (n=284 of
310), respectively, at week 8 (figure 2). Mean changes in
log10 HIV-1 RNA from baseline to week 48 were –3·11 log10 
copies per mL (SD 0·660) in the bictegravir, emtricitabine, 
and tenofovir alafenamide group and –3·08 log10 copies 
per mL (0·719) in the dolutegravir, abacavir, and 
lamivudine group (p=0·65). CD4 cell count increased in 
each treatment group, with mean changes from base-
line to week 48 (observed data, on-treatment values) of 
233 cells per μL (SD 185·2) in the bictegravir, 
emtricitabine, and tenofovir alafenamide group and 
229 cells per μL (188·8) in the dolutegravir, abacavir, and 
lamivudine group (p=0·81).
We did resistance analysis of five participants with 
protocol-defined criteria for resistance testing (n=1 in 
the bictegravir, emtricitabine, and tenofovir alafenamide 
group and n=4 in the dolutegravir, abacavir, and lamivu-
dine group). No treatment-emergent resistance devel-
oped to any component of either treatment regimen (data 
not shown).
An intensive pharmacokinetic substudy was done in a 
subset of the study participants (n=17) in the bictegravir, 
emtricitabine, and tenofovir alafenamide group. Plasma 
concentrations of bictegravir, emtricitabine, and tenofovir 
alafenamide were assessed and the pharmacokinetic 
measures determined. The mean trough concentration 
(Ctau) of bictegravir was 2310 ng per mL (percentage 
coefficient of variation [%CV] 41; appendix p 2), which is 
more than 14-times greater than the protein-adjusted 95% 
effective concentration (162 ng per mL) against wild type 
HIV-1 virus. Exposures of emtricitabine (mean area under 
the plasma concentration–time curve during the dosing 
interval [AUCtau] 10 900 ng/mL per h [%CV 30]) and 
tenofovir alafenamide (206 ng/mL per h [51]) were 
consistent with historical data for these approved drugs in 
HIV-infected individuals (appendix p 2).21,22
Both treatments were well tolerated, with most adverse 
events reported as mild or moderate in severity. Nausea 
was reported less frequently in participants in the 
bictegravir, emtricitabine, tenofovir alafenamide group 
than in those in the dolutegravir, abacavir, and lamivudine 
group (p<0·0001; table 3). Adverse events leading to study 
drug discontinuation were uncommon and occurred in 






Difference (95% CI)* p value†
HIV-1 RNA <50 copies per mL 290 (92·4%) 293 (93·0%) –0·6% (–4·8 to 3·6) 0·78
HIV-1 RNA ≥50 copies per mL 3 (1·0%) 8 (2·5%) ·· ··
HIV-1 RNA ≥50 copies per mL 2 (0·6%) 6 (1·9%) ·· ··
Discontinued because of poor 
efficacy
0 0 ·· ··
Discontinued for other reasons 
(last available HIV-1 RNA 
≥50 copies per mL)‡
1 (0·3%) 2 (0·6%) ·· ··
No virological data 21 (6·7%) 14 (4·4%) ·· ··
Discontinued because of 
adverse event or death
0 4 (1·3%) ·· ··
Discontinued for other reasons 
(last available HIV-1 RNA 
<50 copies per mL)‡
16 (5·1%) 9 (2·9%) ·· ··
Missing data, but receiving 
study drug
5 (1·6%) 1 (0·3%) ·· ··
HIV-1 RNA <50 copies per mL by 
missing-equals-failure analysis
290/314 (92·4%) 294/315 (93·3%) −0·9% (−5·1 to 3·2) 0·65
HIV-1 RNA <50 copies per mL by 
missing-equals-excluded analysis
290/292 (99·3%) 294/301 (97·7%) 1·6% (−0·7 to 4·0) 0·10
Data are n (%) or n/N (%), unless otherwise specified. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. 
DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. * Difference (95·002% CI for snapshot analysis, 95% CI for 
missing-equals-failure and missing-equals-excluded analyses) based on Mantel–Haenszel proportions adjusted by 
baseline HIV-1 RNA (≤100 000 vs >100 000 copies per mL) and region (USA vs ex-USA). †p value based on the 
Cochran–Mantel–Haenszel test, stratified by baseline HIV-1 RNA (≤100 000 vs >100 000 copies per mL) and region (USA 
vs ex-USA). ‡Other reasons include participants who discontinued study drug at the investigator’s discretion, withdrawal 
at the decision of the participant, loss to follow-up, non-compliance with study drug, protocol violation, pregnancy, 
and study termination by the sponsor.
Table 2: Virological outcomes at week 48
Figure 2: Proportion of participants with HIV-1 RNA less than 50 copies per mL
Missing-as-excluded analysis. Error bars represent 95% CIs. B/F/TAF=bictegravir, 
emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, 
and lamivudine.


























lamivudine group due to nausea and generalised rash 
(n=1), thrombocytopenia (n=1), chronic pancreatitis and 
steatorrhoea (n=1), and depression (n=1), all of which were 
deemed by the investigator to be related to study drugs 
(table 3). Participants in the bictegravir, emtricitabine, and 
tenofovir alafenamide group had fewer drug-related 
adverse events than did those in the dolutegravir, abacavir, 
and lamivudine group (table 3); events were primarily mild 
or moderate in severity. The difference between groups 
was driven mainly by drug-related nausea (5% [n=17] vs 
17% [n=55]; p<0·0001). Overall, CNS and psychiatric 
adverse events were equally distributed between treatment 
groups (data not shown). Insomnia was reported in 4% of 
participants in the bictegravir, emtricitabine, and tenofovir 
alafenamide group and 6% of those in the dolutegravir, 
abacavir, and lamivudine group (table 3). No patients died 
during the study. Two women, one in each group, had 
confirmed pregnancies. The participant in the bictegravir, 
emtricitabine, and tenofovir alafenamide group 
discontinued study drug at the time pregnancy was 
confirmed and subsequently delivered a healthy full-term 
infant. The pregnancy in the dolutegravir, abacavir, and 
lamivudine group was terminated with an elective abortion 
and study drug was continued. 46 (15%) participants in 
each group had a grade 3 or 4 laboratory abnormality; 
incidence and types of abnormalities were similar between 
groups (appendix p 3).
We recorded small changes from baseline in hip and 
lumbar spine bone mineral density that were similar 
between patients in the bictegravir, emtricitabine, and 
tenofovir alafenamide and dolutegravir, abacavir, and 
lamivudine groups: mean percentage changes at week 48 
were –0·78% (SD 2·22) versus –1·02% (2·31) at the hip 
(least-squares mean difference 0·238%, 95% CI 
–0·151 to 0·626; p=0·23) and –0·83% (3·19) 
versus –0·60% (3·10) at the lumbar spine (–0·235,
–0·766 to 0·297; p=0·39; figure 3).
No cases of proximal tubulopathy or Fanconi syndrome
were reported in either group and no participant dis-
continued because of a renal adverse event. Increases
from baseline in median serum creatinine and decreases
in eGFR were noted at week 48 for both groups (table 4).
At 48 weeks, percentage changes in quantitative pro-
teinuria (total urinary albumin to urine creatinine ratio)
and tubular proteinuria (retinol binding protein and β2-
microglobulin to urine creatinine ratios) were similar and
did not differ significantly between groups (table 4).
Changes from baseline in fasting lipid measures were
generally similar between groups at week 48 (appendix
p 4). There was a small (–0·1), statistically significant
(p=0·0130) difference in the total cholesterol to HDL ratio
between groups (appendix). The proportion of patients
initiating lipid-modifying drugs during the study did not
differ significantly between the bictegravir, emtricitabine,
and tenofovir alafenamide group and the dolutegravir,
abacavir, and lamivudine group (2·5% [n=8 of 314] vs 2·9%
[n=9 of 315]; p=1·00).
Discussion
Our findings show that efficacy of the fixed-dose 
combination of bictegravir, emtricitabine, and tenofovir 
alafenamide was high, and non-inferior to that of the 
approved fixed-dose combination of dolutegravir, 
abacavir, and lamivudine, with no differences between 
treatment groups in efficacy among subgroups. Viral 
suppression by per-protocol analysis was 99% in both 
treatment groups. No treatment-emergent resistance 
developed to the components of either regimen.
Both regimens were well tolerated; adverse events 
leading to study discontinuation were noted in no 
participants in the bictegravir, emtricitabine, and 
tenofovir alafenamide group and 1% of participants in 
the dolutegravir, abacavir, and lamivudine group. 
However, dolutegravir, abacavir, and lamivudine was 
associated with more adverse events in total than 
bictegravir, emtricitabine, and tenofovir alafenamide, 
primarily driven by nausea. Overall, neuropsychiatric 
and sleep disorder events were similar between groups. 
Changes from baseline in bone mineral density and 
serum creatinine and eGFR were similar between 
treatment groups. No patients had proximal tubulopathy 
or discontinuations for renal adverse events in either 
group, and changes in overall proteinuria and tubular 





Any adverse event 265 (84%) 283 (90%)
Grade 3 or 4 adverse event 23 (7%) 24 (8%)
Serious adverse event 19 (6%) 25 (8%)
Drug-related adverse event 82 (26%) 127 (40%)
Drug-related serious adverse event 1 (<1%) 1 (<1%)
Any adverse event leading to study 
drug discontinuation
0 4 (1%)*
Adverse events occurring with ≥5% incidence in either group
Nausea 32 (10%) 72 (23%)
Diarrhoea 40 (13%) 41 (13%)
Headache 36 (11%) 43 (14%)
Upper respiratory tract infection 20 (6%) 34 (11%)
Nasopharyngitis 23 (7%) 29 (9%)
Fatigue 19 (6%) 27 (9%)
Syphilis 12 (4%) 25 (8%)
Insomnia 14 (4%) 20 (6%)
Arthralgia 11 (4%) 19 (6%)
Vomiting 12 (4%) 17 (5%)
Cough 20 (6%) 8 (3%)
Bronchitis 10 (3%) 16 (5%)
Abdominal pain 9 (3%) 16 (5%)
Data are n (%). B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. 
DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. *Chronic pancreatitis and 
steatorrhoea (n=1), nausea and generalised rash (n=1), depression (n=1), and 
thrombocytopenia (n=1).
Table 3: Adverse events
concentrations were generally similar between groups 
and not deemed clinically relevant, and there were no 
differences in initiation of lipid-lowering drugs.
Findings from this study suggest that bictegravir and 
dolutegravir have similar advantages. Both are potent, 
with high inhibitory quotients;23,24 are highly efficacious 
when combined with two NRTIs; can be taken once a 
day, with or without food and in the absence of pharma-
cokinetic enhancement; and are coformulated with 
NRTIs in fixed-dose combinations. However, the fixed-
dose combination of bictegravir, emtricitabine, and 
tenofovir alafenamide might have advantages over the 
combination of dolutegravir, lamivudine, and abacavir. 
Both dolutegravir and abacavir are associated with 
hypersensitivity reactions. Initiation of treatment with 
dolutegravir, abacavir, and lamivudine must be delayed 
pending HLA B*5701 testing and determination of co-
infection with hepatitis B virus. Furthermore, tenofovir 
alafenamide is active against hepatitis B virus and is 
approved for treatment of hepatitis B as a single drug. 
HIV treatment guidelines recommend tenofovir 
alafenamide or tenofovir disoproxil fumarate as 
components of regimens for treatment of people co-
infected with HIV and hepatitis B virus.1–3 Because use of 
coformulated bictegravir, emtricitabine, and tenofovir 
alafenamide does not require HLA B*5701 testing and 
provides guideline-recommended treatment for 
individuals with HIV and hepatitis B co-infection, this 
combination might lend itself to rapid or same-day 
initiation of treatment in the clinical setting. Some, but 
not all, studies have shown an association between 
abacavir use and an increased risk of myocardial 
infarction, although a pathophysiological underlying 
mechanism has not been defined.3–10 Additionally, 
coformulated bictegravir, emtricitabine, and tenofovir 
alafenamide can be given to individuals with an eGFR of 
30 mL/min or more, whereas use of dolutegravir, 
abacavir, and lamivudine is limited to those with an 
eGFR of more than 50 mL/min. We recorded more 
nausea adverse events in the dolutegravir, abacavir, and 
lamivudine group. This observation is most likely to be 
attributable to differences in gastrointestinal tolerability 
between tenofovir alafenamide and abacavir, since 
gastrointestinal tolerability was similar in the phase 2 
and 3 trials comparing bictegravir with dolutegravir 
when both were combined with emtricitabine and 
tenofovir alafenamide.18,25 Furthermore, findings from 
the ACTG 5202 study indicated a greater incidence of 
nausea with the abacavir and lamivudine NRTI backbone 
than with emtricitabine and tenofovir disoproxil 
fumarate.26
There is growing evidence that the resistance barrier of 
dolutegravir is higher than that of raltegravir and 
elvitegravir. To date, only two cases of possible emergent 
INSTI resistance have been reported in patients taking 
dolutegravir as part of an initial regimen.27,28 Thus far, no 
INSTI resistance has emerged in any patient treated with 
either bictegravir or dolutegravir within combination 
regimens in clinical trials.18,25,29 Although assessment of 
the resistance barrier of a drug cannot be determined by 
clinical trials alone, the lack of observed resistance in 
clinical trials, and the finding of in-vitro activity of 
bictegravir against some dolutegravir-resistant isolates,30 
suggests that bictegravir might have a similarly high 
barrier.
Our study has several limitations. The trial was powered 
for the primary efficacy endpoint after 48 weeks of 
treatment. Thus, adverse events, such as CNS events 
recorded in patients treated with dolutegravir, might 
become apparent after longer durations of use or in 
broader patient populations. Other limitations include a 
small proportion of study participants with advanced HIV 
disease, and a small proportion of female participants.
Figure 3: Mean percentage change from baseline in hip and lumbar spine bone mineral density
As determined by dual energy X-ray absorptiometry scan. Error bars represent 95% CIs. B/F/TAF=bictegravir, 
emtricitabine, and tenofovir alafenamide. DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. *B/F/TAF versus 

























































Baseline 0·90 (0·80 to 1·00) 0·91 (0·81 to 0·99) 0·92
Change at week 48 0·11 (0·03 to 0·17) 0·11 (0·03 to 0·18) 0·78
eGFR (mL/min)†
Baseline 125·9 (107·7 to 146·3) 123·0 (107·0 to 144·3) 0·76
Change at week 48 –10·5 (19·5 to 0·2) –10·8 (–21·6 to –2·4) 0·20
Urine albumin to creatinine ratio (mg/g)
Baseline 5·5 (3·7 to 9·2) 5·4 (3·7 to 9·1) 0·72
Percentage change at week 48 0·6% (–32·0 to 48·9) 6·2% (–23·6 to 57·7) 0·11
Urine β2-microglobulin to creatinine ratio (μg/g)
Baseline 108·1 (71·7 to 184·4) 109·8 (77·6 to 191·8) 0·92
Percentage change at week 48 –23·0% (–57·2 to 19·8) –18·1% (–54·2 to 17·4) 0·40
Urine retinol binding protein to creatinine ratio (μg/g)
Baseline 81·0 (58·3 to 122·4) 83·7 (59·8 to 120·4) 0·55
Percentage change at week 48 13·6% (–20·9 to 63·6) 19·9% (–16·0 to 58·9) 0·34
Data are median (IQR), unless otherwise specified. B/F/TAF=bictegravir, emtricitabine, and tenofovir alafenamide. 
DTG/ABC/3TC=dolutegravir, abacavir, and lamivudine. eGFR=estimated glomerular filtration rate. *p values for 
B/F/TAF versus DTG/ABC/3TC from two-sided Wilcoxon rank-sum tests. †Calculated with the Cockcroft–Gault formula.
Table 4: Changes in quantitative measures of proteinuria
In summary, the fixed-dose combination of bictegravir, 
emtricitabine, and tenofovir alafenamide has high 
antiretroviral efficacy and is non-inferior to the 
combination of dolutegravir, abacavir, and lamivudine, 
with no emergence of drug resistance and no apparent 
disadvantage in terms of adverse events or toxic effects, 
including renal, bone, and metabolic measures. 
Bictegravir, emtricitabine, and tenofovir alafenamide had 
better gastrointestinal tolerability, with less nausea, than 
dolutegravir, abacavir, and lamivudine, presumably 
because of differences between tenofovir alafenamide 
and abacavir. The fixed-dose combination of bictegravir, 
emtricitabine, and tenofovir alafenamide is a promising 
regimen for the initial treatment of HIV infection.
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